Published in Sci Rep on June 22, 2015
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (2015) 1.12
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. J Transl Med (2016) 0.98
Sensitivity of plasma BRAF(mutant) and NRAS(mutant) cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol (2015) 0.87
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget (2016) 0.85
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. PLoS One (2016) 0.84
IDH1 mutation detection by droplet digital PCR in glioma. Oncotarget (2015) 0.80
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags. Theranostics (2016) 0.79
KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients. Int J Mol Sci (2016) 0.79
Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int (2016) 0.79
An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases. Oncogene (2016) 0.78
Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J (2016) 0.78
Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol (2015) 0.77
Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther (2017) 0.76
Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces. Sci Rep (2016) 0.75
Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line. Sci Rep (2016) 0.75
Circulating Tumor DNA as Biomarkers for Cancer Detection. Genomics Proteomics Bioinformatics (2017) 0.75
Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. BMC Res Notes (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin (2010) 1.86
Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers (2005) 1.73
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene (2006) 1.69
Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem (2014) 1.44
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev (2014) 1.39
Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci (2008) 1.30
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer (2014) 1.14
The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 1.08
Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol (2007) 0.94
Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn (2013) 0.91